

DOCKET NO.: ISIS-4976
Application No.: 10/038,335
Office Action Dated: November 29, 2004

PATENT

REMARKS

Claims 8-26 are pending in the present application. Claims 8-10 have been allowed. Claims 11-15, 20-22 have been rejected. Claims 16-19 and 23-26 have been objected to. Claims 11-13 have been cancelled without prejudice. No new matter has been added. Upon entry of the present amendment, claims 8-10 and 14-26 will be pending. Reconsideration is respectfully requested in light of these amendments and the following remarks.

I. Rejection under 35 U.S.C. §112

Claims 11-13 are rejected under 35 U.S.C. §112, first paragraph, as allegedly "failing to comply with the enablement requirement." Applicants note that claims 11-13 have been cancelled without prejudice, rendering this rejection moot.

II. Double Patenting

Claims 14-15 and 20-22 have been rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 17-21 and 23 of U.S. Patent 5,952,490. The Examiner suggests that although the conflicting claims are not identical they are not patentably distinct. Applicants have filed herewith a terminal disclaimer in compliance with 37 CFR 1.321(c). Accordingly, withdrawal of this rejection is respectfully requested.

III. Objection to the Claims

Claims 16-19 and 23-26 have been objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 16-19 depend from claim 14 and claims 23-26 depend from claim 21. Applicants believe the rejection of the base claim has been overcome by filing herewith of the terminal disclaimer. Accordingly, claims 16-19 and 23-26 should no longer depend from a rejected based claim. Withdrawal of this objection is, therefore, respectfully requested.


DOCKET NO.: ISIS-4976
Application No.: 10/038,335
Office Action Dated: November 29, 2004

PATENT

VI. Conclusion

In view of the foregoing, Applicants respectfully submit that the claims are in condition for allowance. An early notice of the same is earnestly solicited. If the Examiner is of a contrary view, the Examiner is requested to contact the undersigned attorney at (760) 603-2767.

Respectfully submitted,


Joshua McLaughlin
Registration No. 50,455

Date: February 28, 2005

ISIS PHARMACEUTICALS, INC.
Patent Department
2292 Faraday Avenue
Carlsbad, CA 92008

Enclosures
-Terminal Disclaimer